MarketWatch ... of the European Union to treat postmenopausal women with advanced hormone receptor-positive, HER2 negative (advanced HR+/HER2 negative) breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole (2).
Sacramento Bee ... of the European Union to treat postmenopausal women with advanced hormone receptor-positive, HER2 negative (advanced HR+/HER2 negative) breast cance...
Medisite Il a été signalé des cas d'asthénie et de somnolence associés à l'utilisation d' anastrozole . La prudence est donc recommandée dans le cadre de la conduite d'automobiles ou de l'utilisation de machines lors de la persistance de ce type de symptômes.
InfoBAE.com El informe se ha llevado a cabo antes de comenzar una prueba denominada "IBIS-II" ("Estudio internacional sobre cáncer de mama"), entre mujeres sanas, que deben consumir " anastrozole ", un fármaco que ya se utiliza en el tratamiento de la enfermedad, ...
PharmaLive (press release) (subscription) ... Afinitor is approved for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer (advanced HR+/HER2 negative) in combination with exemestane after failure of treatment with letrozole or anastrozole ...
MarketWatch ... of the European Union to treat postmenopausal women with advanced hormone receptor-positive, HER2 negative (advanced HR+/HER2 negative) breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole (2).
PharmiWeb.com (press release) ... for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer (advanced HR+/HER2 neg...
